# Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

> **NCT00402727** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 813 (actual)

## Conditions studied

- Abscess
- Wound Infection
- Diabetic Foot
- Ulcer

## Interventions

- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)
- **DRUG:** Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid

## Key facts

- **NCT ID:** NCT00402727
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2014-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402727, "Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00402727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*